{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:26:45Z","timestamp":1794544005540,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Showa University"},{"name":"All Japan Labor Welfare Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs for the above mentioned drugs were determined for MDR-TB by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MDR was observed in 88 (26.0%; 88\/339) isolates. LFX had the highest resistance rate (50.0%; 44\/88), followed by MFX (38.6%; 34\/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4\/88), 3.4% (3\/88), and 4.5% (4\/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2\/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in\n                      <jats:italic>gyrA<\/jats:italic>\n                      with the substitution of codon 94 (34\/45, 75.6%). Two strains with CFZ - BDQ cross resistance had a mutation in the\n                      <jats:italic>Rv0678<\/jats:italic>\n                      gene. Of the four LZD resistant isolates, two carried mutations in\n                      <jats:italic>rplC<\/jats:italic>\n                      gene. For the four isolates resistant to DLM, one isolate had mutations in codon 318 of\n                      <jats:italic>fbiC<\/jats:italic>\n                      gene, and two isolates were with mutations in codon 81 of\n                      <jats:italic>ddn<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provided evidence of the usefulness of new anti-TB drugs in the treatment of MDR-TB in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06024-8","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T03:02:45Z","timestamp":1617850965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China"],"prefix":"10.1186","volume":"21","author":[{"given":"Huiwen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichao","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"6024_CR1","unstructured":"Global tuberculosis report 2019. Geneva: World Health Organization; 2019."},{"key":"6024_CR2","unstructured":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)."},{"issue":"9934","key":"6024_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(13)62639-2","volume":"383","author":"L Wang","year":"2014","unstructured":"Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(13)62639-2.","journal-title":"Lancet."},{"key":"6024_CR4","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2008."},{"issue":"1","key":"6024_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.01035-15","volume":"60","author":"D Zhang","year":"2016","unstructured":"Zhang D, Wang Y, Lu J, Pang Y. In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant mycobacterium tuberculosis isolates. Antimicrob Agents Ch. 2016;60(1):393\u20139. https:\/\/doi.org\/10.1128\/AAC.01035-15.","journal-title":"Antimicrob Agents Ch"},{"issue":"3","key":"6024_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","volume":"43","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. Beijing genotype of mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int Antimicrob Ag. 2014;43(3):231\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.12.007.","journal-title":"Int Antimicrob Ag"},{"issue":"1","key":"6024_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","volume":"45","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Li T, Qu G, Pang Y, Zhao Y. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant mycobacterium tuberculosis isolates. Int Antimicrob Ag. 2015;45(1):71\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.012.","journal-title":"Int Antimicrob Ag"},{"key":"6024_CR8","first-page":"1532","volume":"71","author":"E Schena","year":"2016","unstructured":"Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, et al. Delamanid susceptibility testing of mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system. Int Antimicrob Ag. 2016;71:1532\u20139.","journal-title":"Int Antimicrob Ag"},{"issue":"3","key":"6024_CR9","doi-asserted-by":"publisher","first-page":"e32976","DOI":"10.1371\/journal.pone.0032976","volume":"7","author":"Y Pang","year":"2012","unstructured":"Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, et al. Spoligotyping and drug resistance analysis of mycobacterium tuberculosis strains from national survey in China. PLoS One. 2012;7(3):e32976. https:\/\/doi.org\/10.1371\/journal.pone.0032976.","journal-title":"PLoS One"},{"issue":"6","key":"6024_CR10","doi-asserted-by":"publisher","first-page":"1701633","DOI":"10.1183\/13993003.01633-2017","volume":"50","author":"Y Che","year":"2017","unstructured":"Che Y, Song Q, Yang T, Ping G, Yu M. Fluoroquinolone resistance in multidrug-resistant mycobacterium tuberculosis independent of fluoroquinolone use. Eur Respir J. 2017;50(6):1701633. https:\/\/doi.org\/10.1183\/13993003.01633-2017.","journal-title":"Eur Respir J"},{"issue":"11","key":"6024_CR11","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.21037\/jtd.2019.11.03","volume":"11","author":"HMA Hameed","year":"2019","unstructured":"Hameed HMA, Tan Y, Islam MM, Guo L, Chhotaray C, Wang S, et al. Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant mycobacterium tuberculosis clinical isolates in southern China. J Thorac Dis. 2019;11(11):4613\u201325. https:\/\/doi.org\/10.21037\/jtd.2019.11.03.","journal-title":"J Thorac Dis"},{"issue":"3","key":"6024_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.diagmicrobio.2012.03.025","volume":"73","author":"C Zhu","year":"2012","unstructured":"Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, et al. Molecular characterization of fluoroquinolone-resistant mycobacterium tuberculosis clinical isolates from Shanghai, China. Diagn Micr Infec Dis. 2012;73(3):260\u20133. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.03.025.","journal-title":"Diagn Micr Infec Dis"},{"issue":"5","key":"6024_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/jac\/dkm054","volume":"59","author":"RC Chan","year":"2007","unstructured":"Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, et al. Genetic and phenotypic characterization of drug-resistant mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Ch. 2007;59(5):866\u201373. https:\/\/doi.org\/10.1093\/jac\/dkm054.","journal-title":"J Antimicrob Ch"},{"issue":"5","key":"6024_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jac\/dkm038","volume":"59","author":"AN Umubyeyi","year":"2007","unstructured":"Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, de Rijk PW, et al. Limited fluoroquinolone resistance among mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Ch. 2007;59(5):1031\u20133. https:\/\/doi.org\/10.1093\/jac\/dkm038.","journal-title":"J Antimicrob Ch"},{"issue":"8","key":"6024_CR15","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1128\/AAC.00036-08","volume":"52","author":"I Mokrousov","year":"2008","unstructured":"Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, et al. Molecular characterization of ofloxacin-resistant mycobacterium tuberculosis strains from Russia. Antimicrob Agents Ch. 2008;52(8):2937\u20139. https:\/\/doi.org\/10.1128\/AAC.00036-08.","journal-title":"Antimicrob Agents Ch"},{"issue":"6","key":"6024_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jac\/dki353","volume":"56","author":"TS Huang","year":"2005","unstructured":"Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of mycobacterium tuberculosis complex in a Taiwanese medical Centre: 1995-2003. J Antimicrob Ch. 2005;56(6):1058\u201362. https:\/\/doi.org\/10.1093\/jac\/dki353.","journal-title":"J Antimicrob Ch"},{"issue":"7","key":"6024_CR17","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, et al. Acquired resistance of mycobacterium tuberculosis to bedaquiline. PLoS One. 2014;9(7):e102135. https:\/\/doi.org\/10.1371\/journal.pone.0102135.","journal-title":"PLoS One"},{"key":"6024_CR18","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1128\/AAC.06227-11","volume":"56","author":"P Beckert","year":"2012","unstructured":"Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Ch. 2012;56:2743\u20135.","journal-title":"Antimicrob Agents Ch"},{"issue":"9","key":"6024_CR19","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00308-15","volume":"59","author":"HL Haver","year":"2015","unstructured":"Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of mycobacterium tuberculosis. Antimicrob Agents Ch. 2015;59(9):5316\u201323. https:\/\/doi.org\/10.1128\/AAC.00308-15.","journal-title":"Antimicrob Agents Ch"},{"key":"6024_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","volume":"111","author":"Y Liu","year":"2018","unstructured":"Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis. 2018;111:20\u201330. https:\/\/doi.org\/10.1016\/j.tube.2018.04.008.","journal-title":"Tuberculosis."},{"issue":"2","key":"6024_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in mycobacterium tuberculosis. P Natl Acad Sci USA. 2006;103(2):431\u20136. https:\/\/doi.org\/10.1073\/pnas.0508392103.","journal-title":"P Natl Acad Sci USA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-06024-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T03:05:03Z","timestamp":1617851103000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06024-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6024"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06024-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research has been granted by the Ethics Committee of Chinese center for disease control and prevention, and an informed consent was obtained from each participant\/respondent. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This research including all the paper detail, data, tables and images was consented by all the authors and respondents in this paper for publication. And they will be freely available on the internet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}